M&A Deal Summary

Alcon Acquires Kala Pharmaceuticals - EYSUVIS & INVELTYS

On May 23, 2022, Alcon acquired life science company Kala Pharmaceuticals - EYSUVIS & INVELTYS from KALA BIO for 60M USD

Acquisition Highlights
  • This is Alcon’s 2nd transaction in the Life Science sector.
  • This is Alcon’s 4th largest (disclosed) transaction.
  • This is Alcon’s 8th transaction in the United States.
  • This is Alcon’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2022-05-23
Target Kala Pharmaceuticals - EYSUVIS & INVELTYS
Sector Life Science
Buyer(s) Alcon
Sellers(s) KALA BIO
Deal Type Divestiture
Deal Value 60M USD

Target

Kala Pharmaceuticals - EYSUVIS & INVELTYS

Watertown, Massachusetts, United States
Kala Pharmaceuticals' EYSUVIS & INVELTYS provides loteprednol etabonate suspension) 0.25% pharmaceutical eye drops and loteprednol etabonate suspension) 1%, the only corticosteroid for twice-a-day treatment of post-operative inflammation and pain following ocular surgery.

Search 202,196 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Alcon

Fort Worth, Texas, United States
Category Company
Founded 1945
Sector Medical Products
DESCRIPTION

Alcon, Inc. is an eye care company that researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contacts lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye. Alcon is located in Fort Worth, Texas and was formed in 1945.

DEAL STATS #
Overall 10 of 11
Sector (Life Science) 2 of 3
Type (Divestiture) 2 of 2
State (Massachusetts) 1 of 1
Country (United States) 8 of 9
Year (2022) 1 of 2
Size (of disclosed) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-08 Ivantis

Irvine, California, United States

Ivantis is a designer, developer and commercialize of new technologies to treat eye disease. Ivantis was founded in 2007 and is based in Irvine, California.

Buy $475M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-08-22 Aerie

Durham, North Carolina, United States

Aerie is a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with eye diseases and conditions including open-angle glaucoma, dry eye, and diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD). Aerie was founded in 2005 and is based in Durham, North Carolina.

Buy $770M

Seller(S) 1

SELLER

KALA BIO

Arlington, Massachusetts, United States
Category Company
Founded 2009
Sector Life Science
Employees43
Revenue 4M USD (2022)
DESCRIPTION

KALA BIO is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both the front and back of the eye. KALA BIO was founded in 2009 and is based in Arlington, Massachusetts.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2022) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-15 Combangio

Menlo Park, California, United States

Combangio is a clinical-stage biotechnology company focused on developing regenerative biotherapeutics based on mesenchymal stem cell (“MSC”) secretomes. Combangio’s lead product candidate, CMB-012 (which has been renamed KPI-012), for the treatment of persistent corneal epithelial defect (“PCED”), received orphan drug designation from the U.S. Food and Drug Administration (FDA). Combangio was founded in 2014 and is based in Menlo Park, California.

Buy $16M
Mergr

Product

Company

Legal